Mini-arc
DeviceWe will place a single incision sling at the time of surgery for stress urinary incontinence
Other names: single incision sling
NCT Number: NCT02599051
A randomized control trial to compare the efficacy of the single incision mini-sling to the transobturator sling
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Transobturator slings are one type of sling that has become standard treatment for stress urinary incontinence. However, this procedure involves a total of 3 incisions to perform.
In contrast, single incision slings have been developed to treat stress urinary incontinence by using only one incision.
However, to date the success and complications of these two procedures have not been compared or studied.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
We will place a single incision sling at the time of surgery for stress urinary incontinence
Other names: single incision sling
We will place a transobturator sling at the time of surgery for stress urinary incontinence
Other names: transobturator sling
Time frame: 1 year
The primary outcome was presence of leakage during cough stress test(CST) on examination
Time frame: 1 year
Response to validated questionnaire: Urinary Distress Index(UDI-6) Measures symptoms on three subscales: 1. Irritative 2. Stress 3. Obstructive/Discomfort. The mean value of all questions answered is then multiplied by 25 for the actual score (range 0 to 100) Summary score - Add the scores from the 3 scales together to obtain the summary score (range 0 to 300) The higher the score the greater the perceived impact that pelvic floor dysfunction has on a patient's life.
Time frame: 1 year
Assess if the patient has any complaint of stress urinary incontinence after surgery in follow up visits. This will be history only, no examination.
Time frame: 1 year
Self-assessment of cure is based on 5 point scale, cured, greatly improved, somewhat improved, not improved, and worsened. This is calculated by the number of patients that were analyzed.
Time frame: 1 year
Response to validated questionnaire: Incontinence Impact Questionnaire(IIQ-7) The IIQ measures the impact of urinary incontinence on activities roles, and emotional states. A mean score is derived from each domain, then transferred to give weight to each subscale. Subscale scores range from 0-100. The total IIQ score is calculated by adding the four subscales score with a range of 0-400 possible. A score closer to 0 represents activities not affected at all versus closer to 400 represent activities that were greatly affected.
Time frame: 1 year
Response to validated questionnaire: International Consultation on Incontinence Questionnaire(ICIQ). The ICIQ is a screening tool for incontinence. The scoring scale is 0-21, minimum 0, maximum 21. a higher score indicates greater impairment from incontinence.
Cecilia Calvo
Other
Transobturator Versus Single Incision Slings: 1 Year Results of a Randomized Control Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04114266
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Ghent, Belgium
View Trial DetailsNCT03325543
Behavior, Female Urogenital Diseases
São Paulo, Brazil
View Trial DetailsNCT04171531
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Birmingham, Alabama, United States
View Trial DetailsNCT03672461
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Palo Alto, California, United States
View Trial Details